임상 한눈에 보기

• 5건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 2건 · 완료/종료 10건
• Phase: PHASE2 · PHASE3 · PHASE4
• Status: COMPLETED · ACTIVE_NOT_RECRUITING · RECRUITING
• 주요 endpoint: Percentage of Participants Achieving 20 Percentage (%) Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo · Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Total Score Less Than or Equal to (<=)10 [CDAI Low Disease Activity (LDA)] at Week 12 · Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 · Percentage of Participants Achieving 20% Improvement in ACR20 at Week 24 (Non-Inferiority Versus Tofacitinib) · Percentage of Participants Achieving 50%/70% Improvement in American College of Rheumatology Criteria (ACR50/70) at Week 24 and ACR 20/50/70 at and Week 52 for Treatment Arms Who Started Study Intervention From Day 1
• 등록 대상자(표본 합산): 약 8,184명
• 등록된 결과: ORR 3%
• 핵심: RATIONALE: Drugs used in chemotherapy such as methotrexate and temozolomide use different ways to stop cancer cells from…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.